中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 6
Jun.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(6): 1334-1340

Influencing factors for the prognosis of biopsy proven patients with chronic drug-induced liver injury: An analysis of 255 cases

DOI: 10.3969/j.issn.1001-5256.2022.06.022
  • 1.

    Peking University 302 Clinical Medical School, Beijing 100071, China

  • 2.

    Senior Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

Research funding:

The National Natural Science Foundation of China (82070584);

The National Natural Science Foundation of China (81670527);

The Chinese PLA General Hospital Foundation (YNKTZ2018001)

More Information
  • Corresponding author: ZOU Zhengsheng, zszou302@163.com(ORCID: 0000-0002-1778-269X)
  • Received Date: 2021-11-20
  • Accepted Date: 2022-01-10
  • Published Date: 2022-06-20
    Abstract
  •   Objective  To investigate the influencing factors for the prognosis of adult patients with chronic drug-induced liver injury (DILI).  Methods  A total of 255 patients who were diagnosed with chronic DILI by liver biopsy in The Fifth Medical Center of Chinese PLA General Hospital from January 2014 to December 2018 were enrolled, and according to the liver function after 2 years, they were divided into non-recovery group and recovery group. The two groups were analyzed in terms of the clinical data including age, sex, body mass index, types of drugs used, type of DILI injury, severity of DILI injury, underlying diseases, laboratory markers, liver histology, and 2-year prognosis. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. Univariate and multivariate logistic regression analyses were used to investigate the independent risk factors for the prognosis of chronic DILI.  Results  After 2 years of follow-up, 195 patients (76.5%) achieved the recovery of liver function, while 60 patients (23.5%) did not achieve such recovery. There were significant differences between the two groups in the type of DILI injury (P=0.028), the proportion of patients with diabetes (P=0.048), and the degree of liver fibrosis (P < 0.001), and compared with the recovery group, the non-recovery group had significantly higher levels of baseline white blood cell count, platelet count (PLT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase, and total bile acid and a significantly lower level of cholinesterase (ChE) (all P < 0.05). The baseline characteristics were included in the univariate logistic regression analysis, and the results showed that PLT, ALT, AST, ChE, and fibrosis degree were significantly associated with the prognosis of chronic DILI (all P < 0.05). The multivariate logistic regression analysis of the above variables showed that PLT < 100×109/L (odds ratio [OR]=3.592, 95% confidence interval [CI]: 1.128-11.438, P=0.003) and ALT > 2×upper limit of normal (ULN) (OR=3.080, 95%CI: 1.331-7.127, P=0.009) were independent risk factors for the prognosis of chronic DILI.  Conclusion  When patients meet the diagnostic criteria for chronic DILI, the independent risk factors PLT < 100×109/L and ALT > 2×ULN may be used to screen out the patients who are more likely to have poor prognosis.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [2]
    WANG Q, HUANG A, WANG JB, et al. Chronic drug-induced liver injury: Updates and future challenges[J]. Front Pharmacol, 2021, 12: 627133. DOI: 10.3389/fphar.2021.627133.
    [3]
    WANG Y, WANG Y, WANG L, et al. A comparison study of clinical features and prognosis between herbal and dietary supplements and Wester medicine induced liver injuries[J]. Chin Hepatol, 2021, 26(4): 364-369. DOI: 10.14000/j.cnki.issn.1008-1704.2021.04.007.

    王艳, 王昱, 王岚, 等. 中草药与西药致药物性肝损伤的临床特征及其预后的对比研究[J]. 肝脏, 2021, 26(4): 364-369. DOI: 10.14000/j.cnki.issn.1008-1704.2021.04.007.
    [4]
    JI TT, LU HY, TAN N, et al. A comparative analysis of the clinical features of acute and chronic drug-induced liver injury[J]. J Clin Hepatol, 2020, 36(7): 1556-1561. DOI: 10.3969/j.issn.1001-5256.2020.07.021.

    纪童童, 陆海英, 谭宁, 等. 急、慢性药物性肝损伤临床特征的对比分析[J]. 临床肝胆病杂志, 2020, 36(7): 1556-1561. DOI: 10.3969/j.issn.1001-5256.2020.07.021.
    [5]
    HUANG A, SUN Y, ZOU ZS. Recent research ad-vances in chronicity of drug-induced liver injury[J]. J Clin Hepatol, 2020, 36(3): 501-504. DOI: 10.3969/j.issn.1001-5256.2020.03.004.

    黄昂, 孙颖, 邹正升. 药物性肝损伤慢性化的研究近况[J]. 临床肝胆病杂志, 2020, 36(3): 501-504. DOI: 10.3969/j.issn.1001-5256.2020.03.004.
    [6]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [7]
    FONTANA RJ, HAYASHI PH, BARNHART H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury[J]. Am J Gastroenterol, 2015, 110(10): 1450-1459. DOI: 10.1038/ajg.2015.283.
    [8]
    MEDINA-CALIZ I, ROBLES-DIAZ M, GARCIA-MUÑOZ B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury[J]. J Hepatol, 2016, 65(3): 532-542. DOI: 10.1016/j.jhep.2016.05.003.
    [9]
    CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology, 2015, 148(7): 1340-1352. e7. DOI: 10.1053/j.gastro.2015.03.006.
    [10]
    SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in Mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
    [11]
    JING J, TESCHKE R. Traditional Chinese Medicine and herb-induced liver injury: Comparison with drug-induced liver injury[J]. J Clin Transl Hepatol, 2018, 6(1): 57-68. DOI: 10.14218/JCTH.2017.00033.
    [12]
    LI FL, HUANG ZG, GE CL, et al. Logistic regression analysis of the clinical characteristics and prognostic factors of drug-induced liver injury[J]. J Hepatobiliary Surg, 2019, 27(4): 258-262. DOI: 10.3969/j.issn.1006-4761.2019.04.007.

    李飞龙, 黄赵刚, 葛朝亮, 等. 药物性肝损伤的临床特点及预后因素Logistic回归分析[J]. 肝胆外科杂志, 2019, 27(4): 258-262. DOI: 10.3969/j.issn.1006-4761.2019.04.007.
    [13]
    ZHANG XY, CHEN HQ, BAI C. Clinical characteristics and prognosis of drug-induced liver injury[J]. Contemp Med, 2019, 25 (7): 137-139. DOI: 10.3969/j.issn.1009-4393.2019.07.055.

    张旭艳, 陈慧群, 白成. 药物性肝损伤的临床特点及其预后评估[J]. 当代医学, 2019, 25(7): 137-139. DOI: 10.3969/j.issn.1009-4393.2019.07.055.
    [14]
    BJÖRNSSON E, KALAITZAKIS E, AV KLINTEBERG V, et al. Long- term follow-up of patients with mild to moderate drug-induced liver injury[J]. Aliment Pharmacol Ther, 2007, 26(1): 79-85. DOI: 10.1111/j.1365-2036.2007.03355.x.
    [15]
    LO RE V 3rd, HAYNES K, FORDE KA, et al. Risk of acute liver failure in patients with drug-induced liver injury: Evaluation of Hy's law and a new prognostic model[J]. Clin Gastroenterol Hepatol, 2015, 13(13): 2360-2368. DOI: 10.1016/j.cgh.2015.06.020.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (534) PDF downloads(66) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return